However, it has also been associated with an increased risk of TMN and mutations in TP53 have been reported to promote clonal expansion and the development of resistance in del(5q) MDS treated with lenalidomide34,35. This evidence concerns the gene TP53 and therapy-related myeloid neoplasm.